10-Q: Therapeutic Solutions International Reports First Quarter 2024 Results, Cites Ongoing Losses and Need for Capital

Therapeutic Solutions International reported a net loss of $585,141 for the first quarter of 2024, highlighting ongoing financial challenges and the need for additional capital.

Summary

• Therapeutic Solutions International (TSOI) reported a net loss of $585,141 for the three months ended March 31, 2024, compared to a net loss of $577,881 for the same period in 2023.
• Net sales decreased slightly to $21,814 in Q1 2024 from $23,123 in Q1 2023.
• Operating expenses increased significantly to $687,565 in Q1 2024 from $444,524 in Q1 2023, primarily due to higher consulting, legal, and research and development costs.
• The company's accumulated deficit has reached $20.9 million, and it has a working capital deficit of approximately $1 million as of March 31, 2024.
• TSOI's management has expressed substantial doubt about the company's ability to continue as a going concern without securing additional financing and achieving profitable operations.
• The company is focused on immune modulation and developing treatments for various diseases, including cancer, schizophrenia, and traumatic brain injury.
• TSOI has a nutraceutical division with its flagship product, QuadraMune, and a cellular division focused on stem cell therapies.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including recurring losses, a working capital deficit, and doubts about the company's ability to continue as a going concern. While there are some positive aspects, such as the company's patent portfolio and diverse therapeutic approaches, the overall sentiment is negative due to the financial instability and uncertainty.

Positives

• TSOI has a diverse portfolio of immunotherapies and regenerative medicine technologies.
• The company has made progress in developing its nutraceutical division, including the launch of products on the Amazon platform.
• TSOI has established a Master Cell Bank for its JadiCell product.
• The company has several subsidiaries focused on specific therapeutic areas, such as CTE, COPD, and cancer.
• TSOI has a large portfolio of patents and patent applications.

Negatives

• The company is experiencing recurring losses and has a significant accumulated deficit.
• TSOI has a working capital deficit, indicating potential liquidity issues.
• The company's operating expenses have increased substantially, particularly in consulting and legal fees.
• TSOI's management has expressed substantial doubt about the company's ability to continue as a going concern.
• Net sales have decreased slightly compared to the same period last year.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.
• There is no assurance that TSOI will be able to secure additional funds or obtain them on satisfactory terms.
• The company faces risks related to the development and commercialization of its products.
• TSOI is subject to various government regulations, including those related to product claims and advertising.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company intends to finance operating costs through existing financial resources and may raise additional capital through equity offerings, debt financings, collaborations, and/or licensing arrangements. If adequate funds are not available, the company may be required to delay, reduce the scope of, or curtail its operations.

Management Comments

• Management does not expect existing cash as of March 31, 2024, to be sufficient to fund the Company's operations for at least twelve months from the issuance date of these financial statements.
• The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements.

Industry Context

The company operates in the biotechnology and nutraceutical industries, which are characterized by high research and development costs, regulatory hurdles, and competition. The company's focus on immune modulation and stem cell therapies aligns with current trends in regenerative medicine and personalized healthcare.

Comparison to Industry Standards

• TSOI's financial results, particularly the recurring losses and working capital deficit, are not uncommon for early-stage biotechnology companies.
• Compared to established pharmaceutical companies, TSOI's revenue is minimal, and its reliance on external funding is significant.
• The company's research and development expenses are typical for a company focused on developing novel therapies.
• The company's patent portfolio is a positive sign, but the value of these patents will depend on their successful commercialization.
• The company's focus on stem cell therapies and immunotherapies is in line with current industry trends, but the success of these therapies is not guaranteed.

Legal Proceedings

• TSOI has filed suit against anonymous online posters for defamation.
• Kyle Shepard has sued the Veltmeyer Institute, Dr. James Veltmeyer, TSOI, and Dr. Thomas Ichim for fraud, breach of fiduciary duty, conversion, and intentional interference with contracts.

Related Party Transactions

• The company has unsecured interest-bearing demand notes outstanding to certain officers and directors.
• There are notes payable to related parties, including a Board of Directors member and the Chief Executive Officer.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for dilution from future capital raises.
• Employees may be impacted by potential cost-cutting measures or if the company is unable to continue as a going concern.
• Customers may be affected by potential delays or disruptions in product development and availability.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company intends to continue raising additional capital to fund its operations.
• TSOI plans to continue developing its various therapeutic programs and seek regulatory approvals.
• The company will continue to monitor its financial performance and implement cost-saving measures as needed.

Key Dates

Keywords

Therapeutic Solutions International, immune modulation, stem cell therapy, nutraceuticals, QuadraMune, JadiCell, cancer immunotherapy, schizophrenia, traumatic brain injury, COPD, clinical trials, patents, financial results, going concern